These results may have clinical relevance, as we found that both pharmacologically blocking and genetically silencing Acsl4 significantly improved cardiac function in our mouse model of pressure overload-induced HF, suggesting that ACSL4 may represent a possible target for future therapeutic interventions designed to treat and/or prevent heart failure. Here, ACSL4 is linked to heart failure.